var data={"title":"Fluconazole: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Fluconazole: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6203?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=fluconazole-patient-drug-information\" class=\"drug drug_patient\">see &quot;Fluconazole: Patient drug information&quot;</a> and <a href=\"topic.htm?path=fluconazole-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Fluconazole: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171677\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Diflucan</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171678\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>ACT Fluconazole;</li>\n      <li>Apo-Fluconazole;</li>\n      <li>CanesOral;</li>\n      <li>CO Fluconazole;</li>\n      <li>Diflucan;</li>\n      <li>Diflucan injection;</li>\n      <li>Diflucan One;</li>\n      <li>Diflucan PWS;</li>\n      <li>Dom-Fluconazole;</li>\n      <li>Fluconazole Injection;</li>\n      <li>Fluconazole Injection SDZ;</li>\n      <li>Fluconazole Omega;</li>\n      <li>Monicure;</li>\n      <li>Mylan-Fluconazole;</li>\n      <li>Novo-Fluconazole;</li>\n      <li>PHL-Fluconazole;</li>\n      <li>PMS-Fluconazole;</li>\n      <li>PRO-Fluconazole;</li>\n      <li>Riva-Fluconazole;</li>\n      <li>Taro-Fluconazole</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171730\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antifungal Agent, Azole Derivative;</li>\n      <li>\n        Antifungal Agent, Oral;</li>\n      <li>\n        Antifungal Agent, Parenteral</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171682\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">The daily dose of fluconazole is the same for both oral and IV administration</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Usual dosage range:</b> Oral, IV: 150 mg once <b>or</b> Loading dose: 200 to 800 mg; maintenance: 200 to 800 mg once daily; duration and dosage depend on location and severity of infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Indication-specific dosing:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Blastomycosis (off-label use):</b> Oral: <i>CNS disease:</i> Consolidation: 800 mg daily for &ge;12 months and until resolution of CSF abnormalities (Chapman 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Candidiasis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Candidemia (neutropenic and non-neutropenic patients) (off-label dose) (IDSA [Pappas 2016]):</i> Oral, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Initial therapy (ie, first-line): Loading dose: 800 mg (12 mg/kg) on day 1, then 400 mg daily (6 mg/kg/day) for 14 days after first negative blood culture and resolution of signs/symptoms. <b>Note:</b> Not recommended as first-line therapy in patients with previous azole exposure, critical illness, or if at high risk of <i>C. glabrata</i> infection (elderly, diabetic, malignancy)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Step down therapy (ie, after patient has responded to initial therapy): Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Isolates other than <i>C. glabrata</i>: 400 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Isolates of <i>C. glabrata </i>(fluconazole-susceptible): 800 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Duration: Continue for 14 days after first negative blood culture and resolution of signs/symptoms; step-down therapy to fluconazole (usually after 5 to 7 days in non-neutropenic patients) is recommended only in clinically stable patients with negative repeat cultures and fluconazole-susceptible isolates</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Chronic, disseminated (hepatosplenic) (fluconazole-susceptible isolates):</i> Oral: 400 mg daily (6 mg/kg/day) following several weeks of initial therapy with an amphotericin B lipid formulation or an echinocandin. Continue fluconazole until lesion resolution (usually several months) (IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>CNS candidiasis:</i> Oral, IV: 400 to 800 mg daily (6 to 12 mg/kg/day) as step-down therapy following initial therapy with liposomal amphotericin B (with or without flucytosine); continue fluconazole until signs/symptoms and CSF/radiological abnormalities have resolved (IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Empiric therapy, suspected invasive candidiasis (non-neutropenic patients in the ICU) (alternative therapy) (off-label use):</i> Oral, IV: Loading dose: 800 mg (12 mg/kg) on day 1, then 400 mg daily (6 mg/kg/day); treatment should continue for 14 days in patients with clinical improvement. Consider discontinuing after 4 to 5 days in patients with no clinical response. <b>Note:</b> Not recommended for patients with previous azole exposure or those colonized with azole-resistant <i>Candida</i> spp. (Pappas [IDSA 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Endophthalmitis</i>\n      <i> (with or without vitritis):</i> Oral, IV: Loading dose: 800 mg (12 mg/kg) on day 1, then 400 to 800 mg daily (6 to 12 mg/kg/day) for at least 4 to 6 weeks until examination indicates resolution; for patients with vitritis or with macular involvement (with or without vitritis), an intravitreal injection with voriconazole or amphotericin B deoxycholate is also recommended (IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i> Esophageal:</i> Oral, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Manufacturer&rsquo;s labeling: Loading dose: 200 mg on day 1, then maintenance dose of 100 to 400 mg daily for 21 days and for at least 2 weeks following resolution of symptoms</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Alternate recommendations: 200 to 400 mg daily for 14 to 21 days; chronic suppressive therapy of 100 to 200 mg 3 times weekly may be used for recurrent infections (IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Intertrigo (off-label use):</i> Oral, IV: 50 mg daily or 150 mg once weekly (Coldiron 1991; Nozickova 1998; Stengel 1994)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Intra-abdominal infections</i>: Oral, IV: Loading dose: 800 mg (12 mg/kg) on day 1, then 400 mg daily (6 mg/kg/day); duration of therapy determined by clinical response and source control (IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Intravascular infections (IDSA [Pappas 2016]): </i>Oral, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Endocarditis, native or prosthetic valve: 400 to 800 mg daily (6 to 12 mg/kg/day) for at least 6 weeks after valve replacement surgery (longer durations recommended in patients with perivalvular abscesses or other complications); fluconazole should only be used as step-down therapy in clinically stable, culture-negative patients following initial therapy with an amphotericin B lipid formulation (with or without flucytosine) or an echinocandin; long-term or chronic suppressive therapy with fluconazole in absence of valve replacement surgery or in patients with a prosthetic valve endocarditis: 400 to 800 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Implantable cardiac devices (eg, pacemaker, ICD, VAD) infection: 400 to 800 mg daily (6 to 12 mg/kg/day) for 4 to 6 weeks after device removal (4 weeks for infections limited to generator pockets and at least 6 weeks for infections involving the wires); fluconazole should only be used as step-down in clinically stable, culture-negative patients following initial therapy with an amphotericin B lipid formulation (with or without flucytosine) or an echinocandin; chronic suppressive therapy with fluconazole (following initial antifungal therapy) when VAD cannot be removed and as long as device remains in place: 400 to 800 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Thrombophlebitis, suppurative: 400 to 800 mg daily (6 to 12 mg/kg/day) for at least 2 weeks after candidemia has cleared; fluconazole may be used as initial therapy or as step-down therapy following initial therapy with an amphotericin B lipid formulation or an echinocandin in clinically stable patients with fluconazole-susceptible isolates.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Oropharyngeal:</i> Oral, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Manufacturer's labeling: Loading dose: 200 mg on day 1; maintenance dose 100 mg daily for &ge;2 weeks. <b>Note:</b> Therapy with 100 mg daily is associated with resistance development (Rex 1995).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Alternate recommendations: 100 to 200 mg daily for 7 to 14 days for moderate-to-severe disease; in patients with recurrent infection, chronic therapy of 100 mg 3 times weekly is recommended, if required (IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Osteoarticular (osteomyelitis or septic arthritis):</i> Oral, IV: 400 mg daily (6 mg/kg/day) for 6 to 12 months (osteomyelitis) or 6 weeks (septic arthritis); alternatively, fluconazole 400 mg daily for 6 to 12 months (osteomyelitis) or at least 4 weeks (septic arthritis) may also be used following 2 weeks of initial treatment with an echinocandin or an amphotericin B lipid formulation. In patients with fluconazole-susceptible isolates and septic arthritis involving a prosthetic device which cannot be removed, chronic suppressive therapy with fluconazole 400 mg daily is recommended (IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Peritonitis:</i> Oral, IV: 50-200 mg/day. <b>Note:</b> Some clinicians do not recommend using &lt;200 mg daily (Chen 2004).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Prophylaxis:</i> Oral, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Bone marrow transplant: 400 mg once daily. Patients anticipated to have severe granulocytopenia should start therapy several days prior to the anticipated onset of neutropenia and continue for 7 days after the neutrophil count is &gt;1000 mm<sup>3</sup>.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">High-risk ICU patients in units with high incidence of invasive candidiasis (off-label use): Loading dose: 800 mg (12 mg/kg) on day 1, then 400 mg once daily (6 mg/kg/day) (IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Peritoneal dialysis associated infection (concurrently treated with antibiotics), prevention of secondary fungal infection: 200 mg every 48 hours (Restrepo 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Solid organ transplant: 200 to 400 mg once daily for at least 7 to 14 days (Pappas 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Surgical (perioperative) prophylaxis in high-risk patients undergoing liver, pancreas, kidney, or pancreas-kidney transplantation (off-label use): IV: 400 mg given in the perioperative period and continued in the postoperative period for &le;28 days.  Time of initiation and duration varies with transplant type and operative protocol (Bratzler 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Urinary tract infections:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Manufacturer&rsquo;s labeling: UTI: Oral, IV: 50 to 200 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Alternate recommendations (IDSA [Pappas 2016]):</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Candiduria (asymptomatic), patients undergoing a urologic procedure: Oral: 400 mg once daily (6 mg/kg/day) several days before and after the procedure.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Cystitis (symptomatic): Oral: 200 mg once daily (3 mg/kg/day) for 2 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Fungus balls: Oral: 200 to 400 mg once daily (3 to 6 mg/kg/day); concomitant irrigation of amphotericin B deoxycholate via nephrostomy tubes, if present, is also recommended</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Pyelonephritis: Oral: 200 to 400 mg once daily for 2 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Vaginal/Vulvovaginal:</i> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Uncomplicated: Manufacturer's labeling: 150 mg as a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Complicated or severe: 150 mg every 72 hours for 2 or 3 doses  (Pappas [IDSA 2016]) <b>or</b> 150 mg every 72 hours for 2 doses (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Recurrent: 150 mg once daily for 10 to 14 days, followed by 150 mg once weekly for 6 months (Pappas 2009) <b>or</b> fluconazole 100 mg, 150 mg, or 200 mg every 72 hours (day 1, 4, and 7) for a total of 3 doses, then 100 mg, 150 mg, or 200 mg once weekly for 6 months (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Coccidioidomycosis, treatment (off-label use):</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>HIV-infected (HHS [OI adult 2015]):</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Meningeal infections (consultation with specialist is advised): IV, Oral: 400 to 800 mg once daily; patients who complete initial therapy should be considered for lifelong suppressive therapy using fluconazole 400 mg once daily if CD4 counts remain &lt;250 cells/mm<sup>3</sup>.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Mild infections (eg, focal pneumonia): Oral: 400 mg once daily; patients who complete initial therapy should be considered for lifelong suppressive therapy using fluconazole 400 mg once daily  if CD4 counts remain &lt;250 cells/mm<sup>3</sup>.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Non-HIV infected</i>:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Extrapulmonary, bone and/or joint infection: Oral: A minimum dose of 800 mg once daily for 3 years to lifetime, depending on severity and host immunocompetence. <b>Note: </b>Amphotericin B may be used initially for severe disease and then switched to fluconazole (IDSA [Galgiani 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Extrapulmonary, soft tissue infection (not associated with bone infection): Oral: 400 mg once daily (some experts use up to 800 mg once daily) for a minimum of 6 to 12 months (IDSA [Galgiani 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">HSCT (allogenic or autologous) or solid organ transplant clinically stable patients with active pulmonary infections (acute or chronic): Oral: 400 mg once daily, continued indefinitely or until discontinuation of antirejection therapy (IDSA [Galgiani 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Meningitis: Oral: Initial: 400 to 1200 mg once daily with a lifelong duration (IDSA [Galgiani 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Pneumonia, uncomplicated: Oral: 400 mg once daily (some experts use 800 mg once daily) for 3 to 6 months or longer, depending on response. <b>Note:</b> Antifungal treatment is recommended only for patients with severely debilitating illness or with extensive pulmonary involvement, concurrent diabetes, or frailty due to age or comorbidities (IDSA [Galgiani 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Pneumonia, symptomatic chronic cavitary: Oral: 400 mg once daily for 12 months (Galgiani 2000; IDSA [Galgiani 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Coccidioidomycosis, prophylaxis (off-label use):</b>  Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>HIV-infected patients (HHS [OI adult 2015]): </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Primary prophylaxis in patients with a new positive IgM or IgG serologic test who live in disease-endemic areas and have CD4 counts &lt;250 cells/mm<sup>3</sup>:  400 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Chronic suppressive therapy (secondary prophylaxis): 400 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Non-HIV-infected patients: </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Solid organ transplant patients:<b> Note:</b> The suggested regimens are for patients without active coccidioiomycosis who are undergoing organ transplantation in an endemic area.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Seronegative patients: 200 mg once daily for 6 to 12 months (IDSA [Galgiani 2016]</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Seropositive patients: 400 mg once daily for 6 to 12 months (IDSA [Galgiani 2016]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cryptococcosis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Meningitis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Manufacturer's labeling:</i> Oral, IV: 400 mg for 1 dose, then 200 to 400 mg once daily for 10 to 12 weeks following negative CSF culture</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Alternate dosing: HIV-infected:</i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Induction (alternative to preferred therapy): Oral, IV: 800 to 1,200 mg once daily with concomitant flucytosine for 6 weeks (Perfect 2010) <b>or</b> 400 to 800 mg once daily with concomitant flucytosine for at least 2 weeks (HHS [OI adult 2015]) <b>or</b> 1,200 mg once daily as monotherapy for at least 2 weeks (HHS [OI adult 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Consolidation (preferred therapy): Oral, IV: 400 mg once daily for at least 8 weeks (HHS [OI adult 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Maintenance (suppression) (preferred therapy): Oral: 200 mg once daily for at least 12 months; maintenance therapy may be stopped if the following criteria are fulfilled: induction, consolidation, and at least 12 months of maintenance therapy has been completed, patient remains asymptomatic from cryptococcal infection, and CD4 count &ge;100 cells/mm<sup>3</sup> for &ge;3 months and HIV RNA suppressed in response to effective ART (HHS [OI adult 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Pulmonary (immunocompetent) (off-label use):</b> 400 mg once daily for 6 to 12 months (Perfect 2010)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171707\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=fluconazole-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Fluconazole: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">The daily dose of fluconazole is the same for oral and IV administration</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Usual dosage range:</b> Oral, IV: Loading dose: 6 to 12 mg/kg/dose; maintenance: 3 to 12 mg/kg/dose once daily; duration and dosage depend on location and severity of infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Indication-specific dosing:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Candidiasis:</b> Oral, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Esophageal:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer&rsquo;s recommendation: Loading dose: 6 mg/kg/dose; maintenance: 3-12 mg/kg/dose once daily for 21 days and for at least 2 weeks following resolution of symptoms (maximum: 600 mg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">HIV-exposed/-infected: Loading dose: 6 mg/kg/dose once on day 1; maintenance: 3 to 6 mg/kg/dose once daily for 4 to 21 days (maximum: 400 mg/day) (CDC 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Relapse suppression (HIV-exposed/-infected): 3 to 6 mg/kg/dose once daily (maximum: 200 mg/day) (CDC 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Invasive disease (alternative therapy): 5 to 6 mg/kg/dose every 12 hours for &ge;28 days (maximum: 600 mg/day) (CDC 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Oropharyngeal:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer&rsquo;s recommendation: Loading dose: 6 mg/kg/dose; maintenance: 3 mg/kg/dose once daily for &ge;2 weeks (maximum: 600 mg/day) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">HIV-exposed/-infected: 3 to 6 mg/kg/dose once daily for 7 to 14 days (maximum: 400 mg/day) (CDC 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Surgical (perioperative) prophylaxis in high-risk patients undergoing liver, pancreas, kidney, or pancreas-kidney transplantation (off-label use):</i> IV: 6 mg/kg given in the perioperative period and continued in the postoperative period for &le;28 days (maximum dose 400 mg). Time of initiation and duration varies with transplant type and operative protocol (Bratzler 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Coccidioidomycosis:</b>  Oral, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children: <i>Meningeal infection, or in a stable patient with diffuse pulmonary or disseminated disease</i> (HIV-exposed/-infected): </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Treatment: 5 to 6 mg/kg/dose twice daily (maximum daily dose: 800 mg/<b>day</b>) (CDC 2009) followed by chronic suppressive therapy (see below)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Relapse suppression: 6 mg/kg/dose once daily (maximum daily dose: 400 mg/<b>day</b>) (CDC 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescents: Treatment, primary prophylaxis, or chronic suppressive therapy (secondary prophylaxis): Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cryptococcosis:</b> Oral, IV: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Meningitis:</i> Manufacturer's labeling: 12 mg/kg/dose for 1 dose, then 6 to 12 mg/kg/day for 10-12 weeks following negative CSF culture</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>HIV-exposed/-infected:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>CNS disease (alternative therapy in patients intolerant of amphotericin B):</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Induction: 12 mg/kg/dose for 1 dose, then 6 to 12 mg/kg/day (maximum: 800 mg/day) for &ge;2 weeks (in combination with flucytosine) (CDC 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Consolidation: 10 to 12 mg/kg/day for 8 weeks (Perfect 2010) <b>or</b> 12 mg/kg/dose for 1 dose, then 6 to 12 mg/kg/day (maximum: 800 mg/day) for 8 weeks (CDC 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Maintenance (suppression): 6 mg/kg/day (maximum: 200 mg/day) (CDC 2009; Perfect 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents: Refer to adult dosing. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Non-CNS disease, disseminated (including severe pulmonary disease) (alternative therapy; off-label use):</i> Induction: 12 mg/kg/dose for 1 dose, then 6 to 12 mg/kg/day (maximum: 600 mg/day) (CDC 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Non-CNS disease, localized (including isolated pulmonary disease) (off-label use):</i> 12 mg/kg/dose for 1 dose, then 6 to 12 mg/kg/day (maximum: 600 mg/day).  <b>Note:</b> Duration depends upon infection site and severity (CDC 2009). For patients with pulmonary disease (not delineated by severity), the IDSA recommends a duration of 6 to 12 months (Perfect 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Primary antifungal prophylaxis in pediatric oncology patients (guideline recommendations; Science 2014):</b> Oral, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Allogeneic hematopoietic stem cell transplant (HSCT): Infants &ge;1 month, Children, and Adolescents &lt;19 years: 6 to 12 mg/kg/day (maximum: 400 mg/day), begin at the start of conditioning; continue until engraftment</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Allogeneic HSCT with grades 2 to 4 acute graft-versus-host-disease (GVHD) or chronic extensive GVHD: Begin with GVHD diagnosis, continue until GVHD resolves:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &ge;1 month and Children &lt;13 years: 6 to 12 mg/kg/day (maximum: 400 mg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents &ge;13 years (where posaconazole is contraindicated): 6 to 12 mg/kg/day (maximum: 400 mg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Autologous HSCT with neutropenia anticipated &gt;7 days: Infants &ge;1 month, Children, and Adolescents &lt;19 years: 6 to 12 mg/kg/day (maximum: 400 mg/day), begin at the start of conditioning; continue until engraftment</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS): Infants &ge;1 month, Children, and Adolescents &lt;19 years: 6 to 12 mg/kg/day (maximum: 400 mg/day) during chemotherapy associated neutropenia; alternative antifungals may be suggested for children &ge;13 years in centers with a high local incidence of mold infections or if fluconazole is not available</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171683\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171684\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Manufacturer's labeling: <b>Note:</b> Renal function estimated using the Cockcroft-Gault formula</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">No adjustment for vaginal candidiasis single-dose therapy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">For multiple dosing in adults, administer loading dose of 50 to 400 mg, then adjust daily doses as follows (dosage reduction in children should parallel adult recommendations):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &gt;50 mL/minute: No dosage adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &le;50 mL/minute (no dialysis): Reduce dose by 50%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">End-stage renal disease on intermittent hemodialysis (IHD):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Manufacturer's labeling:</i> 100% of daily dose (according to indication) after each dialysis session; on nondialysis days, patient should receive a reduced dose according to their CrCl.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Alternate recommendations:</i> Doses of 200 to 400 mg every 48 to 72 hours <b>or</b> 100 to 200 mg every 24 hours have been recommended. <b>Note:</b> Dosing dependent on the assumption of 3 times/week, complete IHD sessions (Heintz 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Continuous renal replacement therapy (CRRT) (Heintz 2009; Trotman 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1 to 2 L/hour and minimal residual renal function) and should not supersede clinical judgment:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CVVH: Loading dose of 400 to 800 mg followed by 200 to 400 mg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CVVHD/CVVHDF: Loading dose of 400 to 800 mg followed by 400 to 800 mg every 24 hours (CVVHD or CVVHDF) <b>or</b> 800 mg every 24 hours (CVVHDF)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Higher maintenance doses of 400 mg every 24 hours (CVVH), 800 mg every 24 hours (CVVHD), and 500 to 600 mg every 12 hours (CVVHDF) may be considered when treating resistant organisms and/or when employing combined ultrafiltration and dialysis flow rates of &ge;2 L/hour for CVVHD/CVVHDF (Heintz 2009; Trotman 2005).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15881445\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171652\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mg (50 mL); 200 mg (100 mL); 400 mg (200 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 200 mg (100 mL); 400 mg (200 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension Reconstituted, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Diflucan: 10 mg/mL (35 mL); 40 mg/mL (35 mL) [orange flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg/mL (35 mL); 40 mg/mL (35 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Diflucan: 50 mg, 100 mg, 150 mg, 200 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg, 100 mg, 150 mg, 200 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171637\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171656\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Do not use if cloudy or precipitated. Infuse over ~1 to 2 hours; do not exceed 200 mg/hour.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: May be administered without regard to meals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132520\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 3]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends single gloving for administration of intact tablets or capsules. NIOSH recommends double gloving, a protective gown, and (if there is a potential for vomit or spit up) eye/face protection for administration of an oral liquid/feeding tube administration. For IV compounding, double gloves, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) are recommended. Double gloving and a gown are required during IV administration (NIOSH 2016). Premixed solutions may be excluded from some hazardous drug handling requirements. Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171655\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of candidiasis (esophageal, oropharyngeal, peritoneal, urinary tract, vaginal); systemic candida infections (eg, candidemia, disseminated candidiasis, and pneumonia); cryptococcal meningitis; antifungal prophylaxis in allogeneic bone marrow transplant recipients</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25474718\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Candida intertrigo; Candidiasis, empiric therapy (non-neutropenic patients in the ICU); Candidiasis, prophylaxis against invasive candidiasis (high-risk ICU patients in units with high incidence of invasive candidiasis); Coccidioidomycosis (non-HIV infected); Coccidioidomycosis (prophylaxis/treatment/chronic suppressive therapy) in HIV-infected patients (adolescents and adults); Cryptococcal pneumonia; Primary antifungal prophylaxis in pediatric oncology patients; Surgical prophylaxis (perioperative)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171739\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Fluconazole may be confused with flecainide, FLUoxetine, furosemide, itraconazole, voriconazole</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Diflucan may be confused with diclofenac, Diprivan, disulfiram</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Canesten (oral capsules) [Great Britain] may be confused with Canesten brand name for clotrimazole (various dosage forms) [multiple international markets]; Cenestin brand name estrogens (conjugated A/synthetic) [US, Canada] </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171644\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not always defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Headache (2% to 13%), dizziness (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Skin rash (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Nausea (2% to 7%), abdominal pain (2% to 6%), vomiting (2% to 5%), diarrhea (2% to 3%), dysgeusia (1%), dyspepsia (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Hepatitis, increased serum alkaline phosphatase, increased serum ALT, increased serum AST, jaundice</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Acute generalized exanthematous pustulosis, agranulocytosis, alopecia, anaphylaxis, angioedema, cholestasis, diaphoresis, drowsiness, fatigue, fever, fixed drug eruption, hepatic failure, hypercholesterolemia, hypertriglyceridemia, hypokalemia, insomnia, leukopenia, malaise, myalgia, neutropenia, paresthesia, prolonged Q-T interval on ECG, seizure, Stevens-Johnson syndrome, thrombocytopenia, torsades de pointes, toxic epidermal necrolysis, tremor, vertigo, weakness, xerostomia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171659\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to fluconazole or any component of the formulation (cross-reaction with other azole antifungal agents may occur, but has not been established; use caution); coadministration of terfenadine in adult patients receiving multiple doses of 400 mg or higher or with CYP3A4 substrates which may lead to QTc prolongation (eg, astemizole, cisapride, erythromycin, pimozide, or quinidine) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171641\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Arrhythmias: Cases of QTc prolongation and torsade de pointes associated with fluconazole use have been reported (usually high dose or in combination with agents known to prolong the QT interval); use caution in patients with concomitant medications or conditions which are arrhythmogenic. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; CNS effects: May occasionally cause dizziness or seizures; use caution driving or operating machinery.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatotoxicity: Serious (and sometimes fatal) hepatic toxicity (eg, hepatitis, cholestasis, fulminant hepatic failure) has been observed. Monitor patients who develop abnormal liver function tests for the development of more severe hepatic injury; discontinue fluconazole if signs and symptoms consistent with liver disease develop.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypersensitivity reactions: Anaphylaxis has been reported rarely; use with caution in patients with hypersensitivity to other azoles.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Skin reactions: Rare exfoliative skin disorders have been observed; fatal outcomes have been reported in patients with serious concomitant diseases. Monitor patients with deep seated fungal infections closely for rash development and discontinue if lesions progress. In patients with superficial fungal infections who develop a rash attributable to fluconazole, treatment should also be discontinued.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment:  Use with caution in patients with preexisting hepatic impairment; monitor liver function closely and  discontinue if symptoms consistent with liver disease develop.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment may be necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol;  large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse  (AAP 1997; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Sucrose: Oral suspension contains sucrose; avoid use in patients with fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase insufficiency.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171724\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Inhibits</b> CYP2C19 (strong), CYP2C9 (moderate), CYP3A4 (moderate)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171646\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8450&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Abemaciclib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Abemaciclib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acalabrutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Acalabrutinib.  Management: Reduce acalabrutinib dose to 100 mg once daily with concurrent use of a moderate CYP3A4 inhibitor. Monitor patient closely for both acalabrutinib response and evidence of adverse effects with any concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alfentanil: Fluconazole may increase the serum concentration of Alfentanil.  Management: Monitor for increased anesthetic and respiratory depressant effects if alfentanil is combined with fluconazole. Consider using lower initial doses of alfentanil or an alternative anesthetic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amitriptyline: May enhance the QTc-prolonging effect of Fluconazole. Fluconazole may increase the serum concentration of Amitriptyline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AmLODIPine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of AmLODIPine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphotericin B: Antifungal Agents (Azole Derivatives, Systemic) may diminish the therapeutic effect of Amphotericin B. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Apixaban: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Apixaban. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Aprepitant. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ARIPiprazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Astemizole: Fluconazole may enhance the QTc-prolonging effect of Astemizole. Fluconazole may increase the serum concentration of Astemizole. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Asunaprevir: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Asunaprevir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AtorvaSTATin: Fluconazole may increase the serum concentration of AtorvaSTATin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Avanafil: Fluconazole may increase the serum concentration of Avanafil.  Management: Limit avanafil to a maximum dose of 50 mg per 24-hour period in any patient who is also receiving a moderate inhibitor of CYP3A4 such as fluconazole.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benzhydrocodone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Benzhydrocodone. Specifically, the concentration of hydrocodone may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blonanserin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Blonanserin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bosentan.  Management: Concomitant use of both a CYP2C9 inhibitor and a CYP3A inhibitor or a single agent that inhibits both enzymes with bosentan is likely to cause a large increase in serum concentrations of bosentan and is not recommended. See monograph for details.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Bosentan.  Management: Concomitant use of both a CYP2C9 inhibitor and a CYP3A inhibitor or a single agent that inhibits both enzymes with bosentan is likely to cause a large increase in serum concentrations of bosentan and is not recommended.  See monograph for details.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bosutinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brexpiprazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Brexpiprazole.  Management: The brexpiprazole dose should be reduced to 25% of usual if used together with both a moderate CYP3A4 inhibitor and a strong or moderate CYP2D6 inhibitor, or if a moderate CYP3A4 inhibitor is used in a CYP2D6 poor metabolizer.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromocriptine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bromocriptine.  Management: The bromocriptine dose should not exceed 1.6 mg daily with use of a moderate CYP3A4 inhibitor.  The Cycloset brand specifically recommends this dose limitation, but other bromocriptine products do not make such specific recommendations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Budesonide (Systemic): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Systemic). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Budesonide (Topical): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Topical).  Management: Per US prescribing information, avoid this combination. Canadian product labeling does not recommend strict avoidance. If combined, monitor for excessive glucocorticoid effects as budesonide exposure may be increased.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Busulfan: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Busulfan. Isavuconazonium considerations are addressed in separate monographs. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Channel Blockers: Fluconazole may increase the serum concentration of Calcium Channel Blockers. <b> Exceptions: </b>Clevidipine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Cannabis. More specifically, tetrahydrocannabinol serum concentrations may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Cannabis. More specifically, tetrahydrocannabinol and cannabidiol serum concentrations may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: Fluconazole may increase the serum concentration of CarBAMazepine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Carvedilol: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cilostazol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Cilostazol.  Management: Consider reducing the cilostazol dose to 50 mg twice daily in adult patients who are also receiving moderate inhibitors of CYP3A4.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cilostazol: CYP2C19 Inhibitors may increase the serum concentration of Cilostazol.  Management: Consider reducing the cilostazol dose to 50 mg twice daily in patients who are also receiving inhibitors of CYP2C19.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cisapride: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Cisapride. Isavuconazonium considerations are addressed in separate monographs. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Citalopram: Fluconazole may enhance the QTc-prolonging effect of Citalopram. Fluconazole may increase the serum concentration of Citalopram.  Management: If this combination cannot be avoided, consider a lower dose of citalopram and monitor closely for QTc prolongation and arrhythmias.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clopidogrel: CYP2C19 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Clopidogrel.  Management: Due to a risk for impaired clopidogrel effectiveness with such a combination, carefully consider the need for a strong CYP2C19 inhibitor in patients receiving clopidogrel. Monitor patients closely for evidence of a diminished response to clopidogrel.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cobimetinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Cobimetinib.  Management: Avoid the concomitant use of cobimetinib and moderate CYP3A4 inhibitors. If concurrent short term (14 days or less) use cannot be avoided, reduce the cobimetinib dose to 20 mg daily.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Colchicine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.  Management: Reduce colchicine dose as directed when using with a moderate CYP3A4 inhibitor, and increase monitoring for colchicine-related toxicity.  Use extra caution in patients with impaired renal and/or hepatic function.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Fluconazole may increase the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C19 Substrates (High risk with Inhibitors): CYP2C19 Inhibitors (Strong) may decrease the metabolism of CYP2C19 Substrates (High risk with Inhibitors). <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C9 Substrates (High risk with Inhibitors): CYP2C9 Inhibitors (Moderate) may decrease the metabolism of CYP2C9 Substrates (High risk with Inhibitors). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Substrates (High risk with Inhibitors): CYP3A4 Inhibitors (Moderate) may decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors). <b> Exceptions: </b>Alitretinoin (Systemic); Praziquantel; Trabectedin; Vinorelbine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabigatran Etexilate: Fluconazole may enhance the anticoagulant effect of Dabigatran Etexilate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapoxetine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Dapoxetine.  Management: The dose of dapoxetine should be limited to 30 mg per day when used together with a moderate inhibitor of CYP3A4.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deflazacort: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Deflazacort.  Management: Administer one third of the recommended deflazacort dose when used together with a strong or moderate CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Didanosine: May decrease the absorption of Antifungal Agents (Azole Derivatives, Systemic). Enteric coated didanosine capsules are not expected to affect these antifungals.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Domperidone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Domperidone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DOXOrubicin (Conventional): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of DOXOrubicin (Conventional).  Management: Seek alternatives to moderate CYP3A4 inhibitors in patients treated with doxorubicin whenever possible.  One U.S. manufacturer (Pfizer Inc.) recommends that these combinations be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Dronabinol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Dronabinol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eletriptan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eletriptan.  Management: The use of eletriptan within 72 hours of a moderate CYP3A4 inhibitor should be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eliglustat: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eliglustat.  Management: Use should be avoided under some circumstances.  See full drug interaction monograph for details.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eplerenone: Fluconazole may increase the serum concentration of Eplerenone.  Management: Reduce the starting dose of eplerenone to 25 mg/day; monitor patients closely for increased eplerenone effects.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Erythromycin (Systemic): Fluconazole may enhance the QTc-prolonging effect of Erythromycin (Systemic). Fluconazole may increase the serum concentration of Erythromycin (Systemic). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Estrogen Derivatives. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Etravirine: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Etravirine. Applicable Isavuconazonium considerations are addressed in separate monographs. Etravirine may decrease the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). This would be anticipated with itraconazole or ketoconazole. Etravirine may increase the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). This would be anticipated with voriconazole.  Management: Monitor for increased effects/toxicity of etravirine.  Antifungal dose adjustment may be needed for ketoconazole, itraconazole, or posaconazole but specific dosing guidelines are lacking.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Everolimus: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">FentaNYL: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.  Management: Monitor patients closely for several days following initiation of this combination, and adjust fentanyl dose as necessary.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flibanserin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Flibanserin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluvastatin: Fluconazole may increase the serum concentration of Fluvastatin.  Management: Limit fluvastatin maximum  adult dose to 20 mg twice daily, and monitor for toxic effects of fluvastatin (e.g., myalgia, rhabdomyolysis, liver function test abnormalities), during concomitant treatment.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: Fluconazole may increase the serum concentration of Fosphenytoin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">GuanFACINE: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of GuanFACINE.  Management: Reduce the guanfacine dose by 50% when initiating this combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Halofantrine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Halofantrine.  Management: Extreme caution, with possibly increased monitoring of cardiac status (eg, ECG), should be used with concurrent use of halofantrine with any moderate CYP3A4 inhibitor(s).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of HYDROcodone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HydrOXYzine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of HydrOXYzine.  Management: This combination is specifically contraindicated in some non-U.S. labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibrutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ibrutinib.  Management: When treating B-cell malignancies, decrease ibrutinib to 140 mg daily when combined with moderate CYP3A4 inhibitors. When treating graft versus host disease, monitor patients closely and reduce the ibrutinib dose as needed based on adverse reactions.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ifosfamide: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Ifosfamide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Imatinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Imatinib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ivabradine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivabradine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ivacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivacaftor.  Management: Ivacaftor dose reductions are required; consult full monograph content for specific age- and weight-based recommendations.  No dose adjustment is needed when using ivacaftor/lumacaftor with a moderate CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lomitapide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lomitapide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lornoxicam: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Lornoxicam. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Losartan: Fluconazole may decrease the serum concentration of Losartan. Specifically, fluconazole may decrease the serum concentration of E3174, the more potent active metabolite of losartan. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lovastatin: Fluconazole may increase the serum concentration of Lovastatin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lurasidone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lurasidone.  Management: Lurasidone US labeling recommends reducing lurasidone dose by half with a moderate CYP3A4 inhibitor. Some non-US labeling recommends initiating lurasidone at 20 mg/day and limiting dose to 40 mg/day; avoid concurrent use of grapefruit products.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Manidipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Manidipine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methadone: Fluconazole may enhance the QTc-prolonging effect of Methadone. Fluconazole may increase the serum concentration of Methadone.  Management: Monitor patients closely for evidence of methadone toxicities, including but not limited to respiratory depression and QT-prolongation/torsades de pointes, if combined with fluconazole.  Methadone dose reductions may be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirodenafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Mirodenafil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mizolastine: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Mizolastine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naldemedine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Naldemedine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nalfurafine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Nalfurafine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nalmefene: Fluconazole may increase the serum concentration of Nalmefene. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naloxegol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Naloxegol. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nateglinide: Fluconazole may increase the serum concentration of Nateglinide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neratinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Neratinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nevirapine: Fluconazole may increase the serum concentration of Nevirapine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">NiMODipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Olaparib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Olaparib.  Management: Avoid use of moderate CYP3A4 inhibitors in patients being treated with olaparib, if possible.  If such concurrent use cannot be avoided, the dose of olaparib should be reduced to 150 mg twice daily.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ospemifene: Fluconazole may increase the serum concentration of Ospemifene. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OxyCODONE: CYP3A4 Inhibitors (Moderate) may enhance the adverse/toxic effect of OxyCODONE. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of OxyCODONE. Serum concentrations of the active metabolite Oxymorphone may also be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parecoxib: Fluconazole may increase the serum concentration of Parecoxib.  Management: Use the lowest possible dose of parecoxib in patients who are taking fluconazole.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: Fluconazole may increase the serum concentration of Phenytoin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of Pimecrolimus. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimozide: Antifungal Agents (Azole Derivatives, Systemic) may enhance the arrhythmogenic effect of Pimozide. Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Pimozide. This increase in serum concentrations may lead to QTc interval prolongation and ventricular arrhythmias.  Applicable Isavuconazonium considerations are addressed in separate monographs. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimozide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pimozide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PredniSONE: Fluconazole may increase the serum concentration of PredniSONE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propafenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Propafenone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Proton Pump Inhibitors: Fluconazole may increase the serum concentration of Proton Pump Inhibitors. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNIDine: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of QuiNIDine. Applicable Isavuconazonium considerations are addressed in separate monographs. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ramelteon: Fluconazole may increase the serum concentration of Ramelteon. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ranolazine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ranolazine.  Management: Limit the ranolazine adult dose to a maximum of 500 mg twice daily in patients concurrently receiving moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil, erythromycin, etc.).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Red Yeast Rice: Fluconazole may increase the serum concentration of Red Yeast Rice. Specifically, concentrations of lovastatin and related compounds found in Red Yeast Rice may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifamycin Derivatives: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Rifamycin Derivatives. Only rifabutin appears to be affected. Rifamycin Derivatives may decrease the serum concentration of Antifungal Agents (Azole Derivatives, Systemic).  Management: Avoid these combinations when possible.  Voriconazole and isavuconazonium are considered contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rupatadine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Rupatadine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ruxolitinib: Fluconazole may increase the serum concentration of Ruxolitinib.  Management: This combination should be avoided under some circumstances. See monograph for details.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Saccharomyces boulardii: Antifungal Agents (Systemic, Oral) may diminish the therapeutic effect of Saccharomyces boulardii. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salmeterol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Salmeterol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SAXagliptin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of SAXagliptin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sildenafil: Fluconazole may increase the serum concentration of Sildenafil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Simeprevir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simvastatin: Fluconazole may increase the serum concentration of Simvastatin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sirolimus: Fluconazole may increase the serum concentration of Sirolimus.  Management: Sirolimus dose adjustments will likely be needed when starting/stopping any azole antifungal.  Clinical data suggest sirolimus (adult) dose reductions of 50-90% will be needed when starting an azole antifungal, but specific guidelines are lacking.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Solifenacin: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Solifenacin. Applicable Isavuconazonium considerations are addressed in separate monographs.  Management: The manufacturer recommends not exceeding 5 mg daily of solifenacin during concomitant therapy with ketoconazole, or other potent CYP3A4 enzyme inhibitors.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sonidegib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Sonidegib.  Management: Avoid concomitant use of sonidegib and moderate CYP3A4 inhibitors when possible.  When concomitant use cannot be avoided, limit CYP3A4 inhibitor use to less than 14 days and monitor for sonidegib toxicity (particularly musculoskeletal adverse reactions).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulfonylureas: Fluconazole may increase the serum concentration of Sulfonylureas.  Management: Seek alternatives when possible.  If used together, monitor closely for increased effects of sulfonylureas if fluconazole is initiated/dose increased, or decreased effects if fluconazole is discontinued/dose decreased.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SUNItinib: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of SUNItinib. Applicable Isavuconazonium considerations are addressed in separate monographs.  Management: Consider a reduced dose of sunitinib (minimum of 37.5 mg daily) during concomitant use. Concurrent use with itraconazole is not recommended per itraconazole labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suvorexant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Suvorexant. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Systemic): Fluconazole may increase the serum concentration of Tacrolimus (Systemic).  Management: Monitor tacrolimus concentrations closely and adjust oral tacrolimus dose as necessary when concomitantly administered with fluconazole.  Reduced doses of tacrolimus will likely be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tadalafil: Fluconazole may increase the serum concentration of Tadalafil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tamsulosin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tamsulosin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telithromycin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Telithromycin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Temsirolimus: Fluconazole may increase serum concentrations of the active metabolite(s) of Temsirolimus.  Management: Consider temsirolimus dose reductions or alternatives to fluconazole.  Monitor sirolimus concentrations in all patients receiving fluconazole or any systemic azole antifungal.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Terfenadine: Fluconazole may enhance the QTc-prolonging effect of Terfenadine. Fluconazole may increase the serum concentration of Terfenadine.  Management: Concomitant use of fluconazole at doses of 400 mg/day or greater and terfenadine is contraindicated and should be avoided. If lower doses of fluconazole and terfenadine are combined, monitor patients for QT-prolongation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Tetrahydrocannabinol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tetrahydrocannabinol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tezacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tezacaftor.  Management: When combined with moderate CYP3A4 inhibitors, tezacaftor/ivacaftor (100 mg/150 mg) should be given in the morning, every other day. Ivacaftor (150 mg) alone should be given in the evening, every other day, on alternate days from tezacaftor/ivacaftor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Theophylline Derivatives: Fluconazole may increase the serum concentration of Theophylline Derivatives. <b> Exceptions: </b>Dyphylline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ticagrelor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ticagrelor. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tipranavir: Fluconazole may increase the serum concentration of Tipranavir.  Management: Limit fluconazole adult maximum dose to 200 mg/day in patients treated with tipranavir.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Fluconazole may increase the serum concentration of Tofacitinib.  Management: Reduce the adult dose of tofacitinib to 5 mg daily in patients receiving moderate CYP3A4 inhibitors that strongly inhibit CYP2C19 (e.g., fluconazole, sitaxentan).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tolvaptan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tolvaptan. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trabectedin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Trabectedin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Udenafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Udenafil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ulipristal: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ulipristal.  Management: This is specific for when ulipristal is being used for signs/symptoms of uterine fibroids (Canadian indication). When ulipristal is used as an emergency contraceptive, patients receiving this combination should be monitored for ulipristal toxicity.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vardenafil: Fluconazole may increase the serum concentration of Vardenafil.  Management: Limit vardenafil doses to a maximum of 5 mg per 24-hour period in patients receiving concurrent therapy with a moderate CYP3A4 inhibitor such as fluconazole.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Venetoclax: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Venetoclax.  Management: Reduce the venetoclax dose by at least 50% in patients requiring these combinations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vilazodone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vilazodone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vindesine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vindesine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Fluconazole may increase the serum concentration of Vitamin K Antagonists. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Voriconazole: Fluconazole may increase the serum concentration of Voriconazole. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zidovudine: Fluconazole may decrease the metabolism of Zidovudine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zopiclone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Zopiclone.  Management: The starting adult dose of zopiclone should not exceed 3.75 mg if combined with a moderate CYP3A4 inhibitor. Monitor patients for signs and symptoms of zopiclone toxicity if these agents are combined.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171648\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (single dose for vaginal candidiasis)/D (all other indications) (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171662\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in some animal reproduction studies. Following exposure during the first trimester, malformations have been noted in humans when fluconazole was used in higher doses (&ge;400 mg/day) over extended periods of time (eg, for the duration of pregnancy or intermittently throughout pregnancy). Abnormalities reported include brachycephaly, abnormal facies, abnormal calvarial development, cleft palate, femoral bowing, thin ribs and long bones, arthrogryposis, and congenital heart disease. Use of lower doses (150 mg as a single dose) does not suggest an increase risk to the fetus. However, available data are conflicting and further study is required to determine the risk to the fetus following the use of lower doses and/or shorter durations of therapy of oral fluconazole (FDA Safety Alert 2016).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use of oral fluconazole for vaginal candidiasis is not recommended in pregnant women (HHS [OI adult 2017]; Workowski [CDC 2015]). Most azole antifungals, including fluconazole, are recommended to be avoided during the first trimester of pregnancy (IDSA [Pappas 2016]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171663\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Fluconazole is present in breast milk at concentrations similar to maternal plasma concentrations (Force 1995; Schilling 1993).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The relative infant dose (RID) of fluconazole is 5% to 21% when calculated using the highest breast milk concentration located and compared to an infant therapeutic dose of 3 to 12 mg/kg/day.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In general, breastfeeding is considered acceptable when the RID is &lt;10%; when an RID is &gt;25% breastfeeding should generally be avoided (Anderson 2016; Ito 2000).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The RID of fluconazole was calculated using a milk concentration of 4.1 mcg/mL, providing an estimated daily infant dose via breast milk of 0.62 mg/kg/day. This milk concentration was obtained following maternal administration of oral fluconazole 200 mg daily for 18 days; the apparent elimination half-life of fluconazole in breast milk was 26.9 hours (Schilling 1993).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Serious adverse events in breastfeeding infants have not been reported following maternal use of fluconazole for nipple or breast candidiasis (Bodley 1997; Chetwynd 2002; Moorhead 2011); flushed cheeks, GI upset, loose stools, mucous feces, and somnolence have been reported in breastfed infants (Moorhead 2011).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Although the manufacturer recommends that caution be exercised when administering fluconazole to breastfeeding women, existing recommendations state that fluconazole is considered compatible with breastfeeding when used in usual recommended doses (WHO 2002). Treatment of breastfeeding women with nipple or breast candidiasis with oral fluconazole is common, especially in persistent or recurring infections (Brent 2001). Untreated candida nipple or breast infections may be painful for the mother and can contribute to premature weaning (Brent 2001). The amount of fluconazole contained in the breast milk is not sufficient to treat mucocutaneous candidiasis in the infant (Force 1995; Schilling 1993); concurrent treatment of both the breastfeeding infant and mother may be required (Chetwynd 2002).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171650\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Periodic liver function tests (AST, ALT, alkaline phosphatase) and renal function tests, potassium</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171640\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Interferes with fungal cytochrome P450 activity (lanosterol 14-&alpha;-demethylase), decreasing ergosterol synthesis (principal sterol in fungal cell membrane) and inhibiting cell membrane formation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171658\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Well absorbed; food does not affect extent of absorption</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: ~0.6 L/kg; widely throughout body with good penetration into CSF, eye, peritoneal fluid, sputum, skin, and urine</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Relative diffusion blood into CSF: Adequate with or without inflammation (exceeds usual MICs)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CSF:blood level ratio: Normal meninges: 50% to 90%; Inflamed meninges: ~80%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding, plasma: 11% to 12%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Oral: &gt;90%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Normal renal function: ~30 hours (range: 20 to 50 hours); Elderly: 46.2 hours; Neonates (gestational age 26 to 29 weeks): 73.6 to 46.6 hours (decreases with increasing postnatal age); Pediatric patients 9 months to 15 years: 19.5 to 25 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: Oral: 1 to 2 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (80% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171661\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Fluconazole in Dextrose Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg/100 mL (100 mL): $13.56</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mg/200 mL (200 mL): $15.13</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Fluconazole in Sodium Chloride Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/50 mL 0.9% (50 mL): $10.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg/100 mL 0.9% (100 mL): $11.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mg/200 mL 0.9% (200 mL): $6.60</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (Diflucan Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/mL (35 mL): $193.72</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg/mL (35 mL): $670.16</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (Fluconazole Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/mL (35 mL): $35.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg/mL (35 mL): $129.49</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Diflucan Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (30): $863.36</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (30): $1,356.54</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (12): $863.64</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (30): $2,219.92</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Fluconazole Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (30): $167.13</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (30): $262.62</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (12): $167.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (30): $429.75</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171665\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Afungil (MX);</li>\n      <li>Apicon (BD);</li>\n      <li>Asperlican (VN);</li>\n      <li>Avezol (MY);</li>\n      <li>Baten (DO, EC, GT, HN, PA, SV);</li>\n      <li>Biozole (MY);</li>\n      <li>Burnax (EC);</li>\n      <li>Canazole (BD);</li>\n      <li>Candid (BD);</li>\n      <li>Candifix (ES);</li>\n      <li>Candinil (LK);</li>\n      <li>Candizole (BE);</li>\n      <li>Canesoral (AU);</li>\n      <li>Cryptal (ID);</li>\n      <li>Diaflu (UA);</li>\n      <li>Diflazole (IE);</li>\n      <li>Diflazon (VN);</li>\n      <li>Diflucan (AE, AT, AU, BB, BE, BF, BG, BH, BJ, BM, BS, BZ, CH, CI, CL, CR, CZ, DE, DK, DO, EE, EG, ES, ET, FI, GB, GH, GM, GN, GT, GY, HK, HN, HR, HU, ID, IE, IS, IT, JM, JO, JP, KE, KR, KW, LB, LR, LT, LU, LV, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NI, NL, NO, NZ, PA, PE, PH, PL, PT, QA, RO, RU, SA, SC, SD, SE, SI, SK, SL, SN, SR, SV, TH, TN, TR, TT, TW, TZ, UG, VN, ZA, ZM, ZW);</li>\n      <li>DiflucanOne (AU);</li>\n      <li>Difluvid (MY, PH);</li>\n      <li>Difluzole (KR);</li>\n      <li>Difnazol (KR);</li>\n      <li>Dimycon (HR);</li>\n      <li>Dizole One (AU);</li>\n      <li>Dyflyuzol (UA);</li>\n      <li>Dyzolor (PH);</li>\n      <li>Eapacon (ET);</li>\n      <li>Exomax (HK);</li>\n      <li>FCZ Infusion (ID);</li>\n      <li>Flocan (KR);</li>\n      <li>FLU-D (TW);</li>\n      <li>Flucand (AE, BH, CY, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Flucanol (IL);</li>\n      <li>Flucazol (AE, BH, BR, CY, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Flucazole (NZ);</li>\n      <li>Flucogus (TW);</li>\n      <li>Flucol (IE);</li>\n      <li>Flucon (KR);</li>\n      <li>Flucona (KR);</li>\n      <li>Flucona-Denk (TZ);</li>\n      <li>Fluconal (BD);</li>\n      <li>Fluconaz (PH);</li>\n      <li>Flucoral (ID);</li>\n      <li>Flucoran (NZ);</li>\n      <li>Flucoxan (MX);</li>\n      <li>Flucozal (BR, LK, MT, PK);</li>\n      <li>Fludicon (HK);</li>\n      <li>Fludizol (TH);</li>\n      <li>Fluken (ZW);</li>\n      <li>Flumax (KR);</li>\n      <li>Flumyc (ZW);</li>\n      <li>Flunazol (CY);</li>\n      <li>Flunazole (TW);</li>\n      <li>Flunco (TH);</li>\n      <li>Fluxar (ID);</li>\n      <li>Fluzin (KR);</li>\n      <li>Fluzole (AU, LK);</li>\n      <li>Fluzoral (TH);</li>\n      <li>Forcan (IN, LV, VN);</li>\n      <li>Fukole (MY, PH);</li>\n      <li>Fumay (TW);</li>\n      <li>Funa (TH);</li>\n      <li>Funazol (KR);</li>\n      <li>Funex (CO);</li>\n      <li>Fungata (AT, DE);</li>\n      <li>Fungicon (ZW);</li>\n      <li>Fungostatin (GR);</li>\n      <li>Fungoz (ID);</li>\n      <li>Funzela (PH);</li>\n      <li>Funzol (AE, HR, JO, LB, QA, SA);</li>\n      <li>Fuzolan (ID);</li>\n      <li>Fuzolsel (VN);</li>\n      <li>Kyrin (TH);</li>\n      <li>Medoflucon (CN, SG);</li>\n      <li>Mikosyst (UA);</li>\n      <li>Mutum (AR, PE, VE);</li>\n      <li>Mycocyst (BM, BS, BZ, GY, JM, SR, TT);</li>\n      <li>Mycomox (LV);</li>\n      <li>Mycorest (SG);</li>\n      <li>Mycosyst (HU);</li>\n      <li>Mycozole (PH);</li>\n      <li>Neoconal (KR);</li>\n      <li>Nobzol-1 (CO);</li>\n      <li>Nobzol-2 (CO);</li>\n      <li>Odaft (MY, PH);</li>\n      <li>Omastin (SG);</li>\n      <li>Onecan (LK);</li>\n      <li>Oneflu (KR);</li>\n      <li>Oramax (AE, ET, KW, LB, QA, SA);</li>\n      <li>Oxifungol (MX);</li>\n      <li>Oxole (AU);</li>\n      <li>Sixanol (PY, UY);</li>\n      <li>Spirolac (PY);</li>\n      <li>Stabilanol (ET, IL);</li>\n      <li>Stalene (TH);</li>\n      <li>Syscan (ET, IN);</li>\n      <li>Tavor (EC);</li>\n      <li>Tinazole (KR);</li>\n      <li>Treflucan (AE, BH, CY, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Triflucan (FR, IL, TR);</li>\n      <li>Trigal (BD);</li>\n      <li>Uzol (TW);</li>\n      <li>Zemyc (ID);</li>\n      <li>Zoldicam (MX);</li>\n      <li>Zoleshot (PH);</li>\n      <li>Zolmed (VN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    &lt;800&gt; Hazardous Drugs&mdash;Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aleck KA and Bartley DL, &ldquo;Multiple Malformation Syndrome Following Fluconazole Use in Pregnancy: Report of an Additional Patient,&rdquo; <i>Am J Med Genet</i>, 1997, 72(3):253-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-drug-information/abstract-text/9332650/pubmed\" target=\"_blank\" id=\"9332650\">9332650</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alsaad AM, Kaplan YC, Koren G. Exposure to fluconazole and risk of congenital malformations in the offspring: A systematic review and meta-analysis. <i>Reprod Toxicol</i>. 2015;52:78-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-drug-information/abstract-text/25724389/pubmed\" target=\"_blank\" id=\"25724389\">25724389</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Amichai B and Grunwald MH, &ldquo;Adverse Drug Reactions of the New Oral Antifungal Agents - Terbinafine, Fluconazole, and Itraconazole,&rdquo; <i>Int J Dermatol</i>, 1998, 37(6):410-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-drug-information/abstract-text/9646122/pubmed\" target=\"_blank\" id=\"9646122\">9646122</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al.<i> Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children, 5th ed</i>. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bean LM, Jackson JR, Dobak WJ, Beiswenger TR, Thorp JA. Intra-amniotic fluconazole therapy for Candida albicans intra-amniotic infection. <i>Obstet Gynecol</i>. 2013;121(2 Pt 2 Suppl 1):452-454.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-drug-information/abstract-text/23344406/pubmed\" target=\"_blank\" id=\"23344406\">23344406</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berl T, Wilner KD, Gardner M, et al, &ldquo;Pharmacokinetics of Fluconazole in Renal Failure,&rdquo; <i>J Am Soc Nephrol</i>, 1995, 6(2):242-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-drug-information/abstract-text/7579091/pubmed\" target=\"_blank\" id=\"7579091\">7579091</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bodley V, Powers D. Long-term treatment of a breastfeeding mother with fluconazole-resolved nipple pain caused by yeast: a case study. <i>J Hum Lact.</i>1997;13(4):307-311.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-drug-information/abstract-text/9429366/pubmed\" target=\"_blank\" id=\"9429366\">9429366</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bratzler DW, Dellinger EP, Olsen KM, et al, &ldquo;Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery,&rdquo; <i>Am J Health Syst Pharm</i>, 2013, 70(3):195-283.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-drug-information/abstract-text/23327981/pubmed\" target=\"_blank\" id=\"23327981\">23327981</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brent NB. Thrush in the breastfeeding dyad: results of a survey on diagnosis and treatment. <i>Clin Pediatr (Phila)</i>. 2001;40(9):503-506.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-drug-information/abstract-text/11583049/pubmed\" target=\"_blank\" id=\"11583049\">11583049</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol&mdash;United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &ldquo;Guidelines for Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Adults and Adolescents. Recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, <i>MMWR Recomm Rep</i>, 2009, 58(RR-4):1-207.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-drug-information/abstract-text/19357635/pubmed\" target=\"_blank\" id=\"19357635\">19357635</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chapman SW, Dismukes WE, Proia LA, et al, &quot;Clinical Practice Guidelines for the Management of Blastomycosis: 2008 Update by the Infectious Diseases Society of America,&quot; <i>Clin Infect Dis</i>, 2008, 46(12):1801-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-drug-information/abstract-text/18462107/pubmed\" target=\"_blank\" id=\"18462107\">18462107</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chen CM, Ho MW, Yu WL, et al, &ldquo;Fungal Peritonitis in Peritoneal Dialysis Patients: Effect of Fluconazole Treatment and Use of the Twin-Bag Disconnect System,&rdquo; <i>J Microbiol Immunol Infect</i>, 2004, 37(2):115-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-drug-information/abstract-text/15181494/pubmed\" target=\"_blank\" id=\"15181494\">15181494</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chetwynd EM, Ives TJ, Payne PM, Edens-Bartholomew N. Fluconazole for postpartum candidal mastitis and infant thrush. <i>J Hum Lact. </i>2002;18(2):168-171.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-drug-information/abstract-text/15181494/pubmed\" target=\"_blank\" id=\"15181494\">15181494</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"1990982\"></a>Coldiron BM and Manders SM, &quot;Persistent Candida Intertrigo Treated With Fluconazole,&quot; <i>Arch Dermatol</i>, 1991, 127(2):165-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-drug-information/abstract-text/1990982/pubmed\" target=\"_blank\" id=\"1990982\">1990982</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Como JA and Dismukes WE, &ldquo;Oral Azole Drugs as Systemic Antifungal Therapy,&rdquo; <i>N Engl J Med</i>, 1993, 330(4):263-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-drug-information/abstract-text/8272088/pubmed\" target=\"_blank\" id=\"8272088\">8272088</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Diflucan (fluconazole) [prescribing information]. New York, NY: Pfizer; November 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Edwards JE Jr, Bodey GP, Bowden RA, et al, &ldquo;International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections,&rdquo; <i>Clin Infect Dis</i>, 1997, 25(1):43-59.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-drug-information/abstract-text/9243032/pubmed\" target=\"_blank\" id=\"9243032\">9243032</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eggimann P, Francioli P, Bille J, et al, &ldquo;Fluconazole Prophylaxis Prevents Intra-Abdominal Candidiasis in High-Risk Surgical Patients,&rdquo; <i>Crit Care Med</i>, 1999, 27(6):1066-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-drug-information/abstract-text/10397206/pubmed\" target=\"_blank\" id=\"10397206\">10397206</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    FDA Safety Alert. MedWatch. Fluconazole (Diflucan): Drug Safety Communication - FDA Evaluating Study Examining Use of Oral Fluconazole (Diflucan) in Pregnancy. Food and Drug Administration website. Available at <a href=\"https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm497656.htm\" target=\"_blank\">https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm497656.htm</a>. April 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fluconazole injection [prescribing information]. Lake Forest, IL: Hospira Inc; December 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Force RW, &ldquo;Fluconazole Concentrations in Breast Milk,&rdquo; <i>Pediatr Infect Dis J</i>, 1995, 14(3):235-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-drug-information/abstract-text/7761190/pubmed\" target=\"_blank\" id=\"7761190\">7761190</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Galgiani JN, Ampel NM, Blair JE, et al. 2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Treatment of Coccidioidomycosis. <i>Clin Infect Dis</i>. 2016;63(6):e112-e146. doi: 10.1093/cid/ciw360.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-drug-information/abstract-text/27470238/pubmed\" target=\"_blank\" id=\"27470238\">27470238</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Galgiani JN, Catanzaro A, Cloud GA, et al; Mycoses Study Group. Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis. A randomized, double-blind trial. <i>Ann Intern Med</i>. 2000;133(9):676-686.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-drug-information/abstract-text/11074900/pubmed\" target=\"_blank\" id=\"11074900\">11074900</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goa KL and Barradell LB, &ldquo;Fluconazole. An Update of Its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Use in Major Superficial and Systemic Mycoses in Immunocompromised Patients,&rdquo; <i>Drugs</i>, 1995, 50(4):658-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-drug-information/abstract-text/8536553/pubmed\" target=\"_blank\" id=\"8536553\">8536553</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goodman JL, Winston DJ, Greenfield RA, et al, &ldquo;A Controlled Trial of Fluconazole to Prevent Fungal Infections in Patients Undergoing Bone Marrow Transplantation,&rdquo; <i>N Engl J Med</i>, 1992, 326(13):845-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-drug-information/abstract-text/1542320/pubmed\" target=\"_blank\" id=\"1542320\">1542320</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gould FK, Denning DW, Elliott TS, et al, &ldquo;Guidelines for the Diagnosis and Antibiotic Treatment of Endocarditis in Adults: A Report of the Working Party of the British Society for Antimicrobial Chemotherapy,&rdquo; <i>J Antimicrob Chemother</i>, 2012, 67(2):269-89.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-drug-information/abstract-text/22086858/pubmed\" target=\"_blank\" id=\"22086858\">22086858</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Grant SM and Clissold SP, &ldquo;Fluconazole: A Review of Its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Potential in Superficial and Systemic Mycoses,&rdquo; <i>Drugs</i>, 1990, 39(6):877-916.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-drug-information/abstract-text/2196167/pubmed\" target=\"_blank\" id=\"2196167\">2196167</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heintz BH, Matzke GR, Dager WE, &ldquo;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&rdquo; <i>Pharmacotherapy</i>, 2009, 29(5):562-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-drug-information/abstract-text/19397464/pubmed\" target=\"_blank\" id=\"19397464\">19397464</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. 2017. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Howley MM, Carter TC, Browne ML, et al. Fluconazole use and birth defects in the National Birth Defects Prevention Study. <i>Am J Obstet Gynecol. </i>2016;214(5):657.e1-657.e9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-drug-information/abstract-text/26640069/pubmed\" target=\"_blank\" id=\"26640069\">26640069</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jick SS. Pregnancy outcomes after maternal exposure to fluconazole. <i>Pharmacotherapy. </i>1999;19(2):221-222.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-drug-information/abstract-text/10030772/pubmed\" target=\"_blank\" id=\"10030772\">10030772</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kalish RB, Garry D, Figueroa R. Achalasia with Candida esophagitis during pregnancy. <i>Obstet Gynecol</i>. 1999;94(5 Pt 2):850.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-drug-information/abstract-text/10546761/pubmed\" target=\"_blank\" id=\"10546761\">10546761</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kauffman CA and Carver PL, &ldquo;Antifungal Agents in the 1990s. Current Status and Future Developments,&rdquo; <i>Drugs</i>, 1997, 53(4):539-49.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-drug-information/abstract-text/9098658/pubmed\" target=\"_blank\" id=\"9098658\">9098658</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kowalsky SF and Dixon DM, &ldquo;Fluconazole: A New Antifungal Agent,&rdquo; <i>Clin Pharm</i>, 1991, 10(3):179-94.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-drug-information/abstract-text/2040125/pubmed\" target=\"_blank\" id=\"2040125\">2040125</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Krcmery V Jr, Huttova M, Masar O. Teratogenicity of fluconazole .<i>Pediatr Infect Dis J</i>. 1996;15(9):841.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-drug-information/abstract-text/8878238/pubmed\" target=\"_blank\" id=\"8878238\">8878238</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lee JW, Seibel NL, Amantea M, et al, &ldquo;Safety and Pharmacokinetics of Fluconazole in Children With Neoplastic Diseases,&rdquo; <i>J Pediatr</i>, 1992, 120(6):987-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-drug-information/abstract-text/1593362/pubmed\" target=\"_blank\" id=\"1593362\">1593362</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lopez-Rangel E, Van Allen MI. Prenatal exposure to fluconazole: an identifiable dysmorphic phenotype. <i>Birth Defects Res Part A Clin Mol Teratol</i>. 2005;73(11):919-923.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-drug-information/abstract-text/16265639/pubmed\" target=\"_blank\" id=\"16265639\">16265639</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lyman CA and Walsh TJ, &ldquo;Systemically Administered Antifungal Agents. A Review of Their Clinical Pharmacology and Therapeutic Applications,&rdquo; <i>Drugs</i>, 1992, 44(1):9-35.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-drug-information/abstract-text/1379913/pubmed\" target=\"_blank\" id=\"1379913\">1379913</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mastroiacovo P, Mazzone T, Botto LD, et al, &ldquo;Prospective Assessment of Pregnancy Outcomes After First-Trimester Exposure to Fluconazole,&rdquo; <i>Am J Obstet Gynecol</i>, 1996, 175(6):1645-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-drug-information/abstract-text/8987954/pubmed\" target=\"_blank\" id=\"8987954\">8987954</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mercurio MG and Elewski BE, &ldquo;Thrombocytopenia Caused by Fluconazole Therapy,&rdquo; <i>J Am Acad Dermatol</i>, 1995, 32(3):525-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-drug-information/abstract-text/7868733/pubmed\" target=\"_blank\" id=\"7868733\">7868733</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Molgaard-Nielsen D, Pasternak B, Hviid A. Use of oral fluconazole during pregnancy and the risk of birth defects. <i>N Engl J Med</i>. 2013;369(9):830-839.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-drug-information/abstract-text/23984730/pubmed\" target=\"_blank\" id=\"23984730\">23984730</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Molgaard-Nielsen D, Svanstrom H, Melbye M, Hviid A, Pasternak B. Association Between Use of Oral Fluconazole During Pregnancy and Risk of Spontaneous Abortion and Stillbirth. <i>JAMA</i>. 2016;315(1):58-67.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-drug-information/abstract-text/26746458/pubmed\" target=\"_blank\" id=\"26746458\">26746458</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Moncino MD and Gutman LT, &ldquo;Severe Systemic Cryptococcal Disease in a Child: Review of Prognostic Indicators Predicting Treatment Failure and an Approach to Maintenance Therapy With Oral Fluconazole,&rdquo; <i>Pediatr Infect Dis J</i>, 1990, 9(5):363-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-drug-information/abstract-text/2352821/pubmed\" target=\"_blank\" id=\"2352821\">2352821</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Moorhead AM, Amir LH, O'Brien PW, Wong S. A prospective study of fluconazole treatment for breast and nipple thrush. <i>Breastfeed Rev</i>. 2011;19(3):25-29.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-drug-information/abstract-text/22263374/pubmed\" target=\"_blank\" id=\"22263374\">22263374</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Norgaard M, Pedersen L, Gislum M, et al. Maternal use of fluconazole and risk of congenital malformations: a Danish population-based cohort study. <i>J Antimicrob Chemother</i>. 2008;62(1):172-176.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-drug-information/abstract-text/18400803/pubmed\" target=\"_blank\" id=\"18400803\">18400803</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"9762826\"></a>Nozickova M, Koudelkova V, Kulikova Z, et al, &quot;A Comparison of the Efficacy of Oral Fluconazole, 150 mg/week Versus 50 mg/day, in the Treatment of Tinea Corporis, Tinea Cruris, Tinea Pedis, and Cutaneous Candidosis,&quot; <i>Int J Dermatol</i>, 1998, 37(9):703-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-drug-information/abstract-text/9762826/pubmed\" target=\"_blank\" id=\"9762826\">9762826</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guideline for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2009;48(5):503-535.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-drug-information/abstract-text/19191635/pubmed\" target=\"_blank\" id=\"19191635\">19191635</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2016;62(4):e1-e50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-drug-information/abstract-text/26679628/pubmed\" target=\"_blank\" id=\"26679628\">26679628</a>]</span><span class=\"doi\">10.1093/cid/civ933</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pelz RK, Hendrix CW, Swoboda SM, et al, &ldquo;Double-Blind Placebo-Controlled Trial of Fluconazole to Prevent Candidal Infections in Critically Ill Surgical Patients,&rdquo; <i>Ann Surg</i>, 2001, 233(4):542-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-drug-information/abstract-text/11303137/pubmed\" target=\"_blank\" id=\"11303137\">11303137</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Perfect JR, Dismukes WE, Dromer F, et al, &ldquo;Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>, 2010, 50(3):291-322.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-drug-information/abstract-text/20047480/pubmed\" target=\"_blank\" id=\"20047480\">20047480</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Perry CM, Whittington R, and McTavish D, &ldquo;Fluconazole. An Update of Its Antimicrobial Activity, Pharmacokinetic Properties, and Therapeutic Use in Vaginal Candidiasis,&rdquo; <i>Drugs</i>, 1995, 49(6):984-1006.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-drug-information/abstract-text/7641607/pubmed\" target=\"_blank\" id=\"7641607\">7641607</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pham CP, de Feiter PW, van der Kuy PH, &ldquo;Long QTc Interval and Torsade de Pointes Caused by Fluconazole,&rdquo; <i>Ann Pharmacother</i>, 2006, 40(7):1456-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-drug-information/abstract-text/16849620/pubmed\" target=\"_blank\" id=\"16849620\">16849620</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pursley TJ, Blomquist IK, Abraham J, Andersen HF, Bartley JA. Fluconazole-induced congenital anomalies in three infants. <i>Clin Infect Dis</i>. 1996;22(2):336-340.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-drug-information/abstract-text/8838193/pubmed\" target=\"_blank\" id=\"8838193\">8838193</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Restrepo C, Chacon J, and Manjarres G, &ldquo;Fungal Peritonitis in Peritoneal Dialysis Patients: Successful Prophylaxis With Fluconazole as Demonstrated by Prospective Randomized Control Trial,&rdquo; <i>Perit Dial Int</i>, 2010, 30(6):619-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-drug-information/abstract-text/20634438/pubmed\" target=\"_blank\" id=\"20634438\">20634438</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rex JH, Bennett JE, Sugar AM, &ldquo;A Randomized Trial Comparing Fluconazole With Amphotericin B for the Treatment of Candidemia in Patients Without Neutropenia. Candidemia Study Group and the National Institute,&rdquo; <i>N Engl J Med</i>, 1994, 331(20):1325-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-drug-information/abstract-text/7935701/pubmed\" target=\"_blank\" id=\"7935701\">7935701</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rex JH, Rinaldi MG, and Pfaller MA. &ldquo;Resistance of <i>Candida</i> Species to Fluconazole,&rdquo; <i>Antimicrob Agents Chemother</i>, 1995, 39(1):1-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-drug-information/abstract-text/7695288/pubmed\" target=\"_blank\" id=\"7695288\">7695288</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sanchez JM and Moya G, &ldquo;Fluconazole Teratogenicity,&rdquo; <i>Prenat Diagn</i>, 1998, 18(8):862-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-drug-information/abstract-text/9742580/pubmed\" target=\"_blank\" id=\"9742580\">9742580</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schilling CG, Seay RE, Larson TA, Meier KR. Excretion of fluconazole inhuman breast milk [abstract].<i>Pharmacotherapy</i>, 1993;13(3):287.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Science M, Robinson PD, MacDonald T, Rassekh SR, Dupuis LL, Sung L. Guideline for primary antifungal prophylaxis for pediatric patients with cancer or hematopoietic stem cell transplant recipients. <i>Pediatr Blood Cancer</i>. 2014;61(3):393-400. doi: 10.1002/pbc.24847.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-drug-information/abstract-text/24424789/pubmed\" target=\"_blank\" id=\"24424789\">24424789</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sedlak T, Shufelt C, Iribarren C, et al, &quot;Oral Contraceptive Use and the ECG: Evidence of an Adverse QT Effect on Corrected QT Interval,&quot; <i>Ann Noninvasive Electrocardiol</i>, 2013, 18(4):389-98.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-drug-information/abstract-text/23879279/pubmed\" target=\"_blank\" id=\"23879279\">23879279</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sorensen HT, Nielsen GL, Olesen C, et al, &ldquo;Risk of Malformations and Other Outcomes in Children Exposed to Fluconazole <i>in utero</i>,&rdquo; <i>Br J Clin Pharmacol</i>, 1999, 48(2):234-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-drug-information/abstract-text/10417502/pubmed\" target=\"_blank\" id=\"10417502\">10417502</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"8002145\"></a>Stengel F, Robles-Soto M, Galimberti R, et al, &quot;Fluconazole Versus Ketoconazole in the Treatment of Dermatophytoses and Cutaneous Candidiasis,&quot; <i>Int J Dermatol</i>, 1994, 33(10):726-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-drug-information/abstract-text/8002145/pubmed\" target=\"_blank\" id=\"8002145\">8002145</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America [published online June 18, 2014]. <i>Clin Infect Dis</i>. 2014;59(2):e10-52. doi: 10.1093/cid/ciu296.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-drug-information/abstract-text/24947530/pubmed\" target=\"_blank\" id=\"24947530\">24947530</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Terrell CL, &ldquo;Antifungal Agents. Part II. The Azoles,&rdquo; <i>Mayo Clin Proc</i>, 1999, 74(1):78-100.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-drug-information/abstract-text/9987539/pubmed\" target=\"_blank\" id=\"9987539\">9987539</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trepanier EF and Amsden GW, &ldquo;Current Issues in Onchomycosis,&rdquo; <i>Ann Pharmacother</i>, 1998, 32(2):204-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-drug-information/abstract-text/9496407/pubmed\" target=\"_blank\" id=\"9496407\">9496407</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trotman RL, Williamson JC, Shoemaker DM, et al, &ldquo;Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,&rdquo; <i>Clin Infect Dis</i>, 2005, 41(8):1159-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-drug-information/abstract-text/16163635/pubmed\" target=\"_blank\" id=\"16163635\">16163635</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Updated September 24, 2015. Accessed September 25, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Valtonen M, Tiula E, and Neuvonen PJ, &ldquo;Effect of Continuous Veno-Venous Haemofiltration and Haemodiafiltration on the Elimination of Fluconazole in Patients With Acute Renal Failure,&rdquo; <i>J Antimicrob Chemother</i>, 1997, 40(5):695-700.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-drug-information/abstract-text/9421318/pubmed\" target=\"_blank\" id=\"9421318\">9421318</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vikram HR and Blair JE. &quot;Coccidioidomycosis in Transplant Recipients: A Primer for Clinicians in Nonendemic Areas,&quot; <i>Curr Opin Organ Transplant</i>, 2009, 14(6):606-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-drug-information/abstract-text/19812497/pubmed\" target=\"_blank\" id=\"19812497\">19812497</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Viscoli C, Castagnola E, Fioredda F, et al, &ldquo;Fluconazole in the Treatment of Candidiasis in Immunocompromised Children,&rdquo; <i>Antimicrob Agents Chemother</i>, 1991, 35(2):365-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-drug-information/abstract-text/2024968/pubmed\" target=\"_blank\" id=\"2024968\">2024968</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vucocevic D, Carey EJ, and Blair JE. &quot;Coccidioidomycosis in Liver Transplant Recipients in an Endemic Area,&quot; <i>Am J Transplantation</i>, 2011, 11(1):111-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-drug-information/abstract-text/21087416/pubmed\" target=\"_blank\" id=\"21087416\">21087416</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wassmann S, Nickenig G, and Bohm M, &ldquo;Long QT Syndrome and Torsade de Pointes in a Patient Receiving Fluconazole,&rdquo; <i>Ann Inter Med</i>, 1999, 131(10):797.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-drug-information/abstract-text/10577320/pubmed\" target=\"_blank\" id=\"10577320\">10577320</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wiesinger EC, Mayerhofer S, Wenisch C, Breyer S, Graninger W. Fluconazole in Candida albicans sepsis during pregnancy: case report and review of the literature. <i>Infection. </i>1996;24(3):263-266.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-drug-information/abstract-text/8811369/pubmed\" target=\"_blank\" id=\"8811369\">8811369</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the Eleventh WHO Model List of Essential Drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/23215911</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Workowski KA. Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines.<i>Clin Infect Dis.</i>2015;61 Suppl 8:S759-762.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-drug-information/abstract-text/26602614/pubmed\" target=\"_blank\" id=\"26602614\">26602614</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Workowski KA, Bolan GA; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2015 [published correction appears in <i>MMWR Recomm Rep</i>. 2015;64(33):924]. <i>MMWR Recomm Rep</i>. 2015;64(RR-03):1-137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluconazole-drug-information/abstract-text/26042815 /pubmed\" target=\"_blank\" id=\"26042815 \">26042815 </a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8450 Version 289.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F171677\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F171678\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F171730\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F171682\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F171707\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F171683\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F171684\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15881445\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F171652\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F171637\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F171656\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132520\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F171655\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25474718\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F171739\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F171644\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F171659\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F171641\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F171724\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F171646\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F171648\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F171662\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F171663\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F171650\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F171640\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F171658\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F171661\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F171665\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8450|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=fluconazole-patient-drug-information\" class=\"drug drug_patient\">Fluconazole: Patient drug information</a></li><li><a href=\"topic.htm?path=fluconazole-pediatric-drug-information\" class=\"drug drug_pediatric\">Fluconazole: Pediatric drug information</a></li></ul></div></div>","javascript":null}